跳至主要内容
临床试验/NCT06087731
NCT06087731撤回2 期

Efficacy and Safety of Tocilizumab for Patients With Thyroid-associated Ophthalmopathy

Sun Yat-sen University1 个研究点 分布在 1 个国家开始时间: 2023年9月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
发起方
试验地点
1
主要终点
volume and signal intensity of each extraocular muscles and soft tissue in MRI images

研究概览

简要总结

This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.

详细描述

Thyroid Associated Ophthalmopathy(TAO) is one of autoimmune orbital diseases characterized by enlargement of the extraocular muscles and increase in fatty or/and orbit connective tissue volume affecting the appearance and visual function of the eyes. In TAO pathogenesis, orbital fibroblasts are activated by autoantibodies against the thyrotropin receptor TSHR and the insulin-like growth factor-1 receptor. The fibroblasts then secrete interleukin-6 (IL-6), macrophage chemoattractant protein-1, and transforming growth factor-ß. In orbital preadipocyte fibroblasts, IL-6 increases expression of the thyrotropin receptor TSHR, and the orbital volume is relative to IL-6 mRNA expression. Thus, IL-6 may have several roles in the pathogenesis of TAO. Tocilizumab, a recombinant humanized IgG1 monoclonal antibody against IL-6 receptors, is FDA-approved for the treatment of rheumatoid arthritis, giant cell arteritis and juvenile idiopathic arthritis with a good toleration. The investigators carry this perspective cohort study to evaluate the efficacy of tocilizumab in TAO.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

tocilizumab

Experimental

administrated with tocilizumab (8mg/kg) every four weeks

干预措施: Tocilizumab (Drug)

结局指标

主要结局

volume and signal intensity of each extraocular muscles and soft tissue in MRI images

时间窗: month 1,month 3,month 6

The volume and signal intensity of each extraocular muscles and soft tissue are analyzed in the MRI slides of each patients. each part of each extraocular muscles and soft tissue were measured three times and two trained performers will do this assignment respectively.

Clinical Activity Score

时间窗: month 1,month 3,month 6

Spontaneous orbital pain. Gaze evoked orbital pain. Eyelid swelling that is considered to be due to active (inflammatory phase) GO. Eyelid erythema. Conjunctival redness that is considered to be due to active (inflammatory phase) GO (ignore "equivocal" redness). Chemosis. Inflammation of caruncle or plica

eyelid aperture

时间窗: month 1,month 3,month 6

For the assessment of eyelid aperture, the same millimeter ruler should be used by the same observer. When performed this assessment, participants should relax their eyes and keep looking ahead and the observers should keep the ruler perpendicular to their eyelid.

eyelid lag

时间窗: month 1,month 3,month 6

For the assessment of eyelid aperture, the same millimeter ruler should be used by the same observer. Lid lag is defined that the lid margin distance in downgaze. The upper eyelid positions above (recorded '+') or below (recorded '-') the superior limbus will be measured in millimeters.

exophthalmos

时间窗: month 1,month 3,month 6

For the assessment of exophthalmos, the same Hertel instrument and ideally the same observer should be used on each occasion. Additionally the same intercanthal distance (ICD) should be used on each occasion.

retraction of the upper and lower eyelids

时间窗: month 1,month 3,month 6

For the assessment of eyelid aperture, the same millimeter ruler should be used by the same observer. The upper eyelid positions above (recorded '+') or below (recorded '-') the superior limbus and the lower eyelid positions above (recorded '+') or below (recorded '-') the posterior limbus will be measured in millimeters on the primary position with relaxed status.

次要结局

  • ocular motility(month 1,month 3,month 6)
  • Graves' Ophthalmopathy Quality of Life Scale(month 1,month 3,month 6)
  • inflammatory markers changes(month 1,month 3,month 6)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dan Liang

Dan Liang

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验